Tectonic Q4 net loss $19.2M; TX45 Phase 1b positive, TX2100 Phase 1a started

Tectonic Therapeutic, Inc.

2025-FY EPS reported -$4.05

Q4 net loss $19.2M (vs $12.4M YoY); R&D expenses $16.3M on advancing pipeline.
Cash and equivalents $253.8M as of Dec 31, 2025; expected cash runway into Q4 2028.
TX45 Phase 1b in PH-HFrEF showed 29.2% reduction in PCWP and 17.3% cardiac output improvement.
TX2100 Phase 1a in HHT randomized first subject Feb 2026; topline results expected Q4 2026.
François Nader appointed independent director effective April 1, 2026, to also serve as Board Chair.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.